Trelstar® Six-Month Dosing for Prostate Cancer Patients Launches in Canada
News Oct 08, 2014
Trelstar® (triptorelin pamoate), indicated in Canada for the palliative treatment of hormone dependent advanced prostate cancer, is now available in a six-month dosing option (22.5 mg). The new dosing option eases the burden on patients, with a decreased number of injections and a low incidence of injection site pain, while providing long-term sustained testosterone suppression.
The announcement comes out of Actavis Specialty Pharmaceuticals Co. and Debiopharm Group™, the original developer and sole manufacturer of Trelstar®. Trelstar® was previously marketed by Paladin in Canada, and is currently marketed by Actavis Specialty Pharmaceuticals Co. as of July 1st, 2014.
Prostate cancer is the most common cancer in Canadian men and is the second leading cause of male cancer deaths in Canada. Each year around 23,600 new cases are diagnosed, and close to 4,000 Canadian men die of the disease.
“In patients with advanced prostate cancer, we seek treatment options that will have the most benefit in terms of quality of life and survival,” says Dr. Laurence Klotz, Chief, Urology, Sunnybrook Health Sciences Centre and Professor, Department of Surgery, University of Toronto. “Six-month Trelstar® offers improved quality of life for patients - the requirement for half as many needles and clinic visits makes a difference.”
Trelstar® is an agonist analogue of natural gonadotropin-releasing hormone (GnRH). Similar to other GnRH agonists, it reduces the level of sex hormones, such as testosterone, in the body. Reducing testosterone levels helps slow disease progression in addition to reducing the bone pain, urinary problems and other symptoms of prostate cancer.
“We are committed to developing treatments that make a difference to patients,” says Rob Tessarolo, General Manager, Actavis Specialty Pharmaceuticals Co. “Prostate cancer is the most common cancer in men and a challenging illness. We are pleased to announce the new dosing option for Trelstar® and to welcome a trusted brand back to the Actavis family.”
“We are glad to further strengthen our collaboration with Actavis Specialty Pharmaceuticals Co. who becomes our unique commercial partner in North America for Trelstar®,” says Thierry Mauvernay, Delegate of the Board of Debiopharm Group™. “We share a common philosophy with Actavis, focused on improving quality of life for men suffering from prostate cancer.”
In new studies a novel oxygen-delivery therapeutic restored the function of oxygen-starved heart tissue in an animal model of global hypoxia. Unlike its experimental predecessors, the new drug does not appear to cause systemic side effects or overcorrect with excessive blood oxygenation, which can itself be toxic. Instead, the new drug delivers its precious oxygen cargo only to the tissues that need it most.READ MORE